PEPTI stays in compounded GLP-1s as larger platforms step back
With Hims closing compounded semaglutide to new patients and Ro exiting in 2026, PEPTI continues shipping compounded GLP-1s in all 50 states.
The wire
- 01Hims stopped offering compounded semaglutide to new patients in March 2026 and Ro left compounded GLP-1s the same year.
- 02PEPTI remains available in all 50 states and Washington, D.C., with medication compounded at a US FDA-registered pharmacy and shipped cold.
- 03Eden paused new-patient enrollment mid-2026; how remaining demand redistributes across active providers is not yet clear.
From the source
Read at hellopepti.comHow the intake, physician review and shipping work
Source URL https://hellopepti.com/how-it-works